Povidone

證據等級: L5

預測適應症: 1 個

Povidone: From Pharmaceutical Excipient to Congenital Ichthyosiform Erythroderma

One-Sentence Summary

Povidone (PVP) is a synthetic polymer used almost exclusively as a pharmaceutical excipient (binder, film-former, suspending/solubilizing agent) and does not carry an approved therapeutic indication of its own. The TxGNN model predicts a possible association with Congenital Ichthyosiform Erythroderma, a rare inherited skin-barrier disorder, but this prediction is currently supported by 0 clinical trials and 0 publications, and the underlying mechanistic rationale itself flags the signal as a likely knowledge-graph artifact rather than a genuine pharmacological link.

Quick Overview

Item	Content
Original Indication	Not available — povidone is a pharmaceutical excipient with no approved therapeutic indication of its own
Predicted New Indication	Congenital Ichthyosiform Erythroderma
TxGNN Prediction Score	99.11%
Evidence Level	L5 (model prediction only; no clinical trials or literature)
Canada Market Status	✗ Not Marketed
Number of DINs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for povidone is not available. This is consistent with what is otherwise known about the substance: povidone is not developed or regulated as an active pharmaceutical ingredient with its own indication. It is an inert, high-molecular-weight polyvinylpyrrolidone polymer used across many drug products as a tablet binder, film-forming agent, and suspending/solubilizing vehicle. It has no established receptor target, enzyme inhibition profile, or systemic pharmacological activity.

Congenital Ichthyosiform Erythroderma is a rare, genetically inherited disorder of skin barrier formation and lipid metabolism (commonly linked to genes such as ABCA12, TGM1, and NIPAL4). Its pathophysiology is entirely unrelated to any known excipient function — there is no structural, receptor, or metabolic pathway overlap between an inert polymer excipient and the lipid/keratinization defects that drive this disease.

Taken together, the repurposing rationale itself concludes there is no plausible mechanistic link. The high TxGNN score (99.11%) most likely reflects a co-occurrence confound in the knowledge graph — povidone frequently appears as a vehicle/base ingredient in topical dermatological formulations, which places it near many skin-disease nodes without any causal pharmacological relationship. This prediction should be treated as a likely false positive rather than a genuine repurposing signal.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Canada Market Information

Povidone (as a standalone active ingredient) currently holds no Health Canada market authorizations — 0 DINs are on record, and market status is Not Marketed.

Safety Considerations

Please refer to the package insert for safety information.

(Note: Regulatory label warnings/contraindications data for this candidate is currently missing and is flagged as a Blocking data gap, meaning it cannot yet proceed to formal safety screening — see Next Steps below.)

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a numerically high TxGNN score, this candidate has zero supporting clinical trials or literature (Evidence Level L5), and the mechanistic rationale explicitly identifies the prediction as a probable knowledge-graph artifact — povidone is an inert excipient with no plausible biological pathway connecting it to a genetic skin-barrier disorder. There is currently no basis to advance this candidate beyond initial screening.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain official regulatory label warnings/contraindications before this candidate can enter Stage S1 safety review
Resolve DG002 (High): obtain verified mechanism-of-action data via the DrugBank API to properly assess mechanistic plausibility
Independent orthogonal evidence (e.g., in vitro or case-level data) demonstrating a genuine mechanistic link, given the current rationale suggests this is a false-positive knowledge-graph association
Re-evaluation only if new clinical or literature evidence emerges; otherwise this candidate should remain deprioritized
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.